Logo

Joseph Jimenez

Sep 21, 2018

uBiome has appointed Joseph Jimenez to its board of directors to support the firm's new drug discovery and development efforts. Prior to uBiome, Jimenez served as CEO of Novartis, where he focused on leading global businesses while divesting non-core divisions. Jimenez has a track record of business leadership at several companies, including Clorox, ConAgra, and H.J Heiz. In addition to uBiome's board of directors, Jimenez also serves on the boards of Procter & Gamble and General Motors. In addition, he served on the board of directors at Colgate-Palmolive from 2009 to 2015, and at AstraZeneca from 2002 to 2017.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.